Lendormin (Brotizolam)

Brotizolam, the active ingredient in Lendormin, is a benzodiazepine presented as a tablet for oral use. It is prescribed to manage insomnia in adult patients who have difficulty initiating or maintaining sleep. Its rapid onset of action and relatively short half‑life support short‑term treatment while minimizing residual daytime sedation.

GNH USA supplies Lendormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches that meet EU regulatory standards.

Brotizolam is a benzodiazepine sedative‑hypnotic that acts on the central nervous system to treat sleep disorders. - Insomnia (sleep onset): helps patients fall asleep more quickly. - Insomnia (sleep maintenance): reduces nighttime awakenings and improves sleep continuity. - Short‑term insomnia treatment: provides relief for acute sleep disturbances, typically limited to a few weeks of therapy.

Brotizolam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling sleepy during the day. - Dizziness: light‑headedness or imbalance. - Dry mouth: reduced salivation. - Fatigue: decreased energy.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Dependence and withdrawal: risk of physical dependence with abrupt stop. - Paradoxical agitation: increased anxiety or aggression.

Before using Lendormin, consider the following safety measures. - Medical supervision: use only under a prescriber's direction. - Alcohol avoidance: do not consume alcoholic beverages while taking the drug. - Elderly caution: start with the lowest effective dose due to increased sensitivity. - Duration limit: limit therapy to short‑term periods, generally not exceeding 4 weeks. - Hepatic/renal assessment: evaluate liver and kidney function before initiating treatment. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Brotizolam can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Alcohol and other CNS depressants: may cause profound sedation and respiratory depression. - Opioids: combined use can enhance central nervous system depression. - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Brotizolam plasma levels. - Other benzodiazepines: additive sedative effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Antihistamines: can increase drowsiness. - Certain antidepressants (e.g., fluoxetine): may modestly raise drug concentrations. - NSAIDs: may increase risk of gastrointestinal bleeding when combined with sedatives.